vs

Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and Nauticus Robotics, Inc. (KITT). Click either name above to swap in a different company.

FATE THERAPEUTICS INC is the larger business by last-quarter revenue ($1.4M vs $1.1M, roughly 1.3× Nauticus Robotics, Inc.). On growth, Nauticus Robotics, Inc. posted the faster year-over-year revenue change (124.4% vs -26.4%). Nauticus Robotics, Inc. produced more free cash flow last quarter ($-5.0M vs $-112.0M). Over the past eight quarters, FATE THERAPEUTICS INC's revenue compounded faster (-15.7% CAGR vs -18.6%).

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

Nauticus Robotics, Inc. develops and manufactures autonomous underwater robots, intelligent marine operation systems, and provides tailored robotic services for clients across offshore energy, maritime defense, and ocean scientific research sectors, with core markets covering North America and global coastal operation regions.

FATE vs KITT — Head-to-Head

Bigger by revenue
FATE
FATE
1.3× larger
FATE
$1.4M
$1.1M
KITT
Growing faster (revenue YoY)
KITT
KITT
+150.8% gap
KITT
124.4%
-26.4%
FATE
More free cash flow
KITT
KITT
$107.1M more FCF
KITT
$-5.0M
$-112.0M
FATE
Faster 2-yr revenue CAGR
FATE
FATE
Annualised
FATE
-15.7%
-18.6%
KITT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FATE
FATE
KITT
KITT
Revenue
$1.4M
$1.1M
Net Profit
$-19.2M
Gross Margin
Operating Margin
-531.0%
Net Margin
-1812.8%
Revenue YoY
-26.4%
124.4%
Net Profit YoY
37.9%
77.3%
EPS (diluted)
$-7.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FATE
FATE
KITT
KITT
Q4 25
$1.4M
$1.1M
Q3 25
$1.7M
$2.0M
Q2 25
$1.9M
$2.1M
Q1 25
$1.6M
Q4 24
$1.9M
$471.2K
Q3 24
$3.1M
Q2 24
$6.8M
$501.7K
Q1 24
$1.9M
$464.4K
Net Profit
FATE
FATE
KITT
KITT
Q4 25
$-19.2M
Q3 25
$-32.3M
$-6.6M
Q2 25
$-34.1M
$-7.5M
Q1 25
$-37.6M
Q4 24
$-84.5M
Q3 24
$-47.7M
Q2 24
$-38.4M
$4.5M
Q1 24
$-48.0M
$-72.8M
Operating Margin
FATE
FATE
KITT
KITT
Q4 25
-531.0%
Q3 25
-1995.1%
-297.3%
Q2 25
-1938.5%
-307.0%
Q1 25
-2534.1%
Q4 24
-1312.1%
Q3 24
-1703.9%
Q2 24
-665.7%
-1198.4%
Q1 24
-2652.9%
-1195.1%
Net Margin
FATE
FATE
KITT
KITT
Q4 25
-1812.8%
Q3 25
-1852.4%
-335.9%
Q2 25
-1786.6%
-359.1%
Q1 25
-2309.5%
Q4 24
-17940.7%
Q3 24
-1551.0%
Q2 24
-567.4%
905.1%
Q1 24
-2493.7%
-15686.1%
EPS (diluted)
FATE
FATE
KITT
KITT
Q4 25
$-7.31
Q3 25
$-0.27
$-2.60
Q2 25
$-0.29
$-0.26
Q1 25
$-0.32
Q4 24
$-267.45
Q3 24
$-0.40
Q2 24
$-0.33
$-1.12
Q1 24
$-0.47
$-58.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FATE
FATE
KITT
KITT
Cash + ST InvestmentsLiquidity on hand
$203.7M
$7.0M
Total DebtLower is stronger
$21.5M
Stockholders' EquityBook value
$207.2M
$7.0M
Total Assets
$318.9M
$42.6M
Debt / EquityLower = less leverage
3.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FATE
FATE
KITT
KITT
Q4 25
$203.7M
$7.0M
Q3 25
$215.4M
$5.5M
Q2 25
$222.8M
$2.7M
Q1 25
$240.4M
Q4 24
$279.1M
$1.2M
Q3 24
$296.9M
Q2 24
$304.9M
$8.1M
Q1 24
$121.3M
$6.2M
Total Debt
FATE
FATE
KITT
KITT
Q4 25
$21.5M
Q3 25
Q2 25
Q1 25
Q4 24
$28.9M
Q3 24
Q2 24
$109.5M
Q1 24
$118.6M
Stockholders' Equity
FATE
FATE
KITT
KITT
Q4 25
$207.2M
$7.0M
Q3 25
$234.1M
$-4.1M
Q2 25
$261.4M
$-5.7M
Q1 25
$288.4M
Q4 24
$318.7M
$-20.4M
Q3 24
$362.3M
Q2 24
$397.0M
$-91.5M
Q1 24
$426.1M
$-112.8M
Total Assets
FATE
FATE
KITT
KITT
Q4 25
$318.9M
$42.6M
Q3 25
$343.7M
$42.8M
Q2 25
$371.6M
$41.9M
Q1 25
$398.7M
Q4 24
$440.7M
$22.7M
Q3 24
$495.0M
Q2 24
$528.8M
$31.2M
Q1 24
$569.9M
$29.4M
Debt / Equity
FATE
FATE
KITT
KITT
Q4 25
3.06×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FATE
FATE
KITT
KITT
Operating Cash FlowLast quarter
$-106.1M
$-4.1M
Free Cash FlowOCF − Capex
$-112.0M
$-5.0M
FCF MarginFCF / Revenue
-8183.9%
-470.4%
Capex IntensityCapex / Revenue
434.8%
86.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-199.6M
$-21.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FATE
FATE
KITT
KITT
Q4 25
$-106.1M
$-4.1M
Q3 25
$-24.4M
$-4.9M
Q2 25
$-24.6M
$-7.4M
Q1 25
$-33.8M
Q4 24
$-122.9M
$-4.2M
Q3 24
$-29.4M
Q2 24
$-32.3M
$-8.4M
Q1 24
$-33.4M
$-6.7M
Free Cash Flow
FATE
FATE
KITT
KITT
Q4 25
$-112.0M
$-5.0M
Q3 25
$-26.6M
$-4.9M
Q2 25
$-25.9M
$-7.4M
Q1 25
$-35.0M
Q4 24
$-123.6M
$-4.3M
Q3 24
$-29.9M
Q2 24
$-32.4M
$-8.4M
Q1 24
$-33.4M
$-7.0M
FCF Margin
FATE
FATE
KITT
KITT
Q4 25
-8183.9%
-470.4%
Q3 25
-1526.5%
-249.8%
Q2 25
-1360.7%
-354.5%
Q1 25
-2148.9%
Q4 24
-6645.4%
-903.5%
Q3 24
-973.1%
Q2 24
-477.8%
-1678.0%
Q1 24
-1736.9%
-1504.1%
Capex Intensity
FATE
FATE
KITT
KITT
Q4 25
434.8%
86.4%
Q3 25
126.5%
0.1%
Q2 25
71.4%
0.0%
Q1 25
73.4%
Q4 24
39.2%
7.4%
Q3 24
16.1%
Q2 24
0.8%
5.5%
Q1 24
4.5%
69.8%
Cash Conversion
FATE
FATE
KITT
KITT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-1.85×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons